This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.

What’s new

Patient Information Booklet for patients on ELIQUIS® for treatment of DVT / PE or prevention of recurrent DVT / PE in adults

This booklet is intended only for patients prescribed ELIQUIS for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults and should only be given to patients prescribed ELIQUIS for this indication.1 This booklet is not intended to replace the Patient Information Leaflet.

This booklet may be read in its electronic form (PDF), or it may printed and read.
If a Patient Information Booklet is printed, please ensure that:
  • It is printed in its entirety. Please do not attempt to print and use individual pages in isolation, as it has been designed to be printed in its entirety
  • Its content is not edited or altered in any way
  • It is printed in colour
  • It is printed in A4 size
  • The pages are placed in the correct order as per the page numbering

Please select the language of the Patient Information Booklet you would like to view below:

FOOTNOTES

DVT = Deep Vein Thrombosis   PE = Pulmonary Embolism

REFERENCE

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.